Eswatini vs Guatemala: Average cost of multi drug-resistant tuberculosis treatment
Eswatini
840 constant 2022 US$
in 2024
Guatemala
813 constant 2022 US$
in 2024
Eswatini rank
59th
Guatemala rank
61st
Average cost of multi drug-resistant tuberculosis treatment over time
- Eswatini
- Guatemala
How they compare
Eswatini currently reports 840 constant 2022 US$ against 813 constant 2022 US$ in Guatemala, a difference of 27 constant 2022 US$.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Eswatini ahead.
Eswatini ranks 59th and Guatemala ranks 61st of 92 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Guatemala | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 6,118 constant 2022 US$ | 784.33 constant 2022 US$ | 5,334 constant 2022 US$ | Eswatini |
| 2020s | 2,824 constant 2022 US$ | 781.2 constant 2022 US$ | 2,043 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Eswatini or Guatemala?
- Eswatini, at 840 constant 2022 US$ against 813 constant 2022 US$ in Guatemala as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Eswatini and Guatemala?
- 27 constant 2022 US$, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Guatemala?
- 8 years are reported by both, from 2017 to 2024.
- How do Eswatini and Guatemala rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Eswatini ranks 59th and Guatemala ranks 61st of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.